ExodusPoint Capital Management LP Boosts Stock Position in DexCom, Inc. (NASDAQ:DXCM)

ExodusPoint Capital Management LP boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 197.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 466,414 shares of the medical device company’s stock after buying an additional 309,714 shares during the period. ExodusPoint Capital Management LP owned approximately 0.12% of DexCom worth $36,273,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Versant Capital Management Inc purchased a new stake in shares of DexCom in the fourth quarter worth $25,000. Private Trust Co. NA boosted its stake in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares in the last quarter. TD Private Client Wealth LLC grew its position in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 167 shares during the last quarter. Larson Financial Group LLC increased its stake in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new position in DexCom in the fourth quarter worth about $38,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Citigroup increased their price target on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and increased their target price for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Morgan Stanley upped their price target on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Finally, Cfra Research upgraded DexCom to a “hold” rating in a report on Friday, March 21st. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average price target of $99.82.

Insider Transactions at DexCom

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 105,009 shares of company stock valued at $8,044,178 over the last quarter. 0.30% of the stock is currently owned by company insiders.

DexCom Stock Up 1.2 %

DXCM opened at $68.14 on Thursday. The firm’s 50 day simple moving average is $81.24 and its two-hundred day simple moving average is $77.04. The company has a market capitalization of $26.63 billion, a PE ratio of 47.65, a PEG ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $141.99. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.